1. Lp(a): a New Pathway to Target?

   • Nick S. Nurmohamed
   • Jordan M. Kraaijenhof
   • Erik S. G. Stroes

   Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors) Open access 06 September 2022 Pages: 831 - 838

   

2. A Review of Statin Intolerance: a Focus on Statin-Attributed Muscle Symptoms

   • Carl E. Orringer
   • Jelani K. Grant
   • Lale Tokgozoglu

   Nonstatin Drugs (L. Tokgozoglu and A.L. Catapano, Section Editors) 24 August 2022 Pages: 839 - 847

   

3. Ultra-processed Foods and Cardiometabolic Health Outcomes: from Evidence to Practice

   • Filippa Juul
   • Andrea L. Deierlein
   • Niyati Parekh

   Nutrition (K. Petersen, Section Editor) 07 September 2022 Pages: 849 - 860

   

4. Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease

   • Ishaan Jindal
   • Xiao Wang

   Genetics and Genomics (R.A. Hegele and L. Brunham, Section Editors) 22 August 2022 Pages: 861 - 866

   

5. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?

   • Maurício Reis Pedrosa
   • Denise Reis Franco
   • Freddy Goldberg Eliaschewitz

   Cardiometabolic Disease and Treatment (R. Santos, Section Editor) 31 August 2022 Pages: 867 - 884

   

6. Best Practices for Designing Informative Trials Including Women

   • Johny Nicolas
   • Madison Edens
   • Roxana Mehran

   Women and Ischemic Heart Disease (J.M. Peña and F. Lin, Section Editors) 26 August 2022 Pages: 885 - 888